Isolator Synergy Ablation System
Commercial- Indications
- Persistent Atrial Fibrillation
Company intelligence / Profile preview
AtriCure, Inc.
Mason, Ohio, United Statesopenpaymentsdata.cms.gov ↗
- Ownership
- Public · ATRC
- Employees
- ~1300
- Development stage
- Commercial
01
Overview
AtriCure's Isolator Synergy Ablation System is FDA-approved for persistent Afib treatment. The CONVERGE IDE clinical trial showed an 18% difference in favor of the hybrid Convergent procedure compared to endocardial catheter ablation alone for persistent Afib patients. The company is currently conducting the LeAAPS clinical trial, which will enroll up to 6,500 patients at up to 250 centers worldwide to evaluate the AtriClip system for stroke prevention in cardiac surgery patients[6][8].
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Surgical devicesablation systemsleft atrial appendage management devices
- Industry
- Surgical Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Population Health Research Institute (PHRI)
04
Financials
- Market cap
- $2.7B
- Total revenue
- $153.6M
- Enterprise value
- $2.6B
Beyond the preview
Go deeper on AtriCure, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AtriCure, Inc..